IDXX
IDEXX Laboratories, Inc. NASDAQ$562.97
Mkt Cap $44.8B
52w Low $465.00
32.1% of range
52w High $769.98
50d MA $588.05
200d MA $641.44
P/E (TTM)
43.1x
EV/EBITDA
37.5x
P/B
28.3x
Debt/Equity
0.7x
ROE
66.0%
P/FCF
51.4x
RSI (14)
—
ATR (14)
—
Beta
1.72
50d MA
$588.05
200d MA
$641.44
Avg Volume
533.7K
About
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test k…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | TNS | 3.41 | 3.47 | +1.8% | — | — | — | — | — | — | — | — |
| Feb 2, 2026 | TNS | 2.93 | 3.08 | +5.1% | 639.60 | -0.6% | -1.1% | -1.1% | +0.5% | +0.6% | +0.8% | — |
| Nov 3, 2025 | TNS | 3.14 | 3.40 | +8.3% | 722.94 | -0.8% | -0.1% | -0.1% | -0.4% | -1.3% | -2.0% | — |
| Aug 4, 2025 | TNS | 3.28 | 3.63 | +10.7% | 682.78 | -0.9% | -6.0% | -6.0% | -8.6% | -4.8% | -3.6% | — |
| May 1, 2025 | TNS | 2.85 | 2.96 | +3.9% | 471.38 | +1.4% | +0.1% | +0.1% | +0.8% | +0.5% | +3.2% | — |
| Feb 3, 2025 | TNS | 2.39 | 2.62 | +9.6% | 469.04 | -1.0% | -0.9% | -0.9% | -0.1% | -1.8% | -2.0% | — |
| Oct 31, 2024 | TNS | 2.68 | 2.80 | +4.5% | 406.92 | +0.4% | +2.5% | +2.5% | +1.9% | +2.2% | +4.1% | — |
| Aug 6, 2024 | TNS | 2.88 | 3.02 | +4.9% | 469.37 | +0.5% | -0.5% | -0.5% | +3.1% | +2.9% | +2.2% | — |
| May 1, 2024 | TNS | 2.67 | 2.81 | +5.2% | 468.04 | -0.5% | +1.7% | +1.7% | +2.7% | +1.9% | +3.3% | — |
| Feb 5, 2024 | TNS | 2.12 | 2.32 | +9.4% | 572.12 | +0.7% | -0.9% | -0.9% | +0.0% | +0.3% | +0.0% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | UBS | Maintains | Neutral → Neutral | — | $574.95 | $575.16 | +0.0% | -1.2% | -3.7% | -2.5% | -1.3% | — |
| Mar 31 | Stifel | Maintains | Buy → Buy | — | $557.09 | $560.04 | +0.5% | +0.9% | +1.4% | +2.2% | +3.7% | +3.2% |
| Feb 9 | Piper Sandler | Maintains | Neutral → Neutral | — | $644.61 | $647.72 | +0.5% | -0.7% | +0.3% | +0.6% | -4.3% | -2.4% |
| Feb 5 | Barclays | Maintains | Overweight → Overweight | — | $642.94 | $643.83 | +0.1% | +0.1% | +0.3% | -0.5% | +0.6% | +0.9% |
| Feb 3 | UBS | Maintains | Neutral → Neutral | — | $639.60 | $635.59 | -0.6% | -1.1% | +0.5% | +0.6% | +0.8% | +0.0% |
| Feb 3 | BTIG | Maintains | Buy → Buy | — | $639.60 | $635.59 | -0.6% | -1.1% | +0.5% | +0.6% | +0.8% | +0.0% |
| Nov 4 | UBS | Maintains | Neutral → Neutral | — | $722.94 | $717.44 | -0.8% | -0.1% | -0.4% | -1.3% | -2.0% | -1.8% |
| Nov 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $722.94 | $717.44 | -0.8% | -0.1% | -0.4% | -1.3% | -2.0% | -1.8% |
| Nov 4 | BTIG | Maintains | Buy → Buy | — | $722.94 | $717.44 | -0.8% | -0.1% | -0.4% | -1.3% | -2.0% | -1.8% |
| Nov 4 | JP Morgan | Maintains | Overweight → Overweight | — | $722.94 | $717.44 | -0.8% | -0.1% | -0.4% | -1.3% | -2.0% | -1.8% |
Recent Filings
8-K · 2.02
!! High
IDEXX Laboratories, Inc. -- 8-K 2.02: Earnings Results
IDEXX Laboratories reported quarterly earnings results, with full details available in the accompanying press release, providing investors insight into the company's operational performance and financial health.
May 5
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
IDXX's departure of a key executive, with accelerated vesting of equity awards, signals leadership transition costs and potential talent loss that could impact operational execution and shareholder value.
Mar 26
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Abbott Laboratories' appointment of a new executive effective April 1, 2026, signals potential strategic shifts in operations or leadership direction that could affect near-term stock performance and investor confidence in company management.
Mar 18
8-K
DENTSPLY SIRONA Inc. -- 8-K Filing
DENTSPLY SIRONA strengthened its board with three experienced executives from dental and financial sectors, including Morgan Stanley's former investment banking leader and IDEXX's ex-CFO, signaling potential strategic shifts ahead.
Feb 26
8-K · 5.02
!!! Very High
DENTSPLY SIRONA Inc. -- 8-K 5.02: Executive Change
DENTSPLY SIRONA appointed James D. Forbes as director while Willie A. Deese resigned, signaling potential strategic shifts in board composition and governance priorities.
Feb 24
8-K · 5.02
!!! Very High
Idexx Laboratories Inc -- 8-K 5.02: Executive Change
IDEXX Laboratories announces board member Anne Szostak's retirement, with no reported disagreements concerning company operations or policies.
Feb 13
8-K · 5.02
!!! Very High
Piper Sandler Companies -- 8-K 5.02: Executive Change
Piper Sandler Companies appointed Stuart M. Essig as a director, expanding its board leadership potentially with his industry expertise.
Feb 4
8-K
Idexx Laboratories Inc -- 8-K Filing
IDEXX Laboratories reported fourth quarter 2025 revenue growth of 14% as reported and 12% organically, driven by strong performance in its CAG Diagnostics recurring revenue segment.
Feb 2
Data updated apr 25, 2026 2:59pm
· Source: massive.com